The first step toward a personalized approach was the implementation of immunohistochemical biomarkers (ER, PR, HER2, and Ki-67) in the diagnostic workup of newly diagnosed breast cancer patients since they guide diagnostic and treatment decisions. The gene discussed is MKI67; the disease is breast carcinoma.